Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 10, 2006, Pages 1047-1055

  Alyea, Edwin P ^a,b   Kim, Haesook T ^a   Ho, Vincent ^a,b   Cutler, Corey ^a,b   DeAngelo, Daniel J ^a,b   Stone, Richard ^a,b   Ritz, Jerome ^a,b   Antin, Joseph H ^a,b   Soiffer, Robert J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute leukemia; Allogeneic; Graft versus leukemia; Myelodysplastic syndrome

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; RISK ASSESSMENT; STEM CELL MOBILIZATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VEIN OCCLUSION; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; AGED; BONE MARROW TRANSPLANTATION; BUSULFAN; CYCLOPHOSPHAMIDE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; REOPERATION; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 33750205692     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.06.003     Document Type: Article

References (24)

1. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961-968
2. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104 (2004) 1550-1558
3. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
4. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24 (2006) 444-453
5. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Eng J Med. 331 (1994) 896-903
6. Stone R.M., Berg D.T., George S.L., et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 332 (1995) 1671-1677
7. Stone R.M., Berg D.T., George S.L., et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98 (2001) 548-553
8. Stone R.M. Postremission therapy in adults with acute myeloid leukemia. Semin Hematol 38 (2001) 17-23
9. Meloni G., De Fabritis P., Pulsoni A., et al. Acute myelogenous leukemia in first relapse treated with two consecutive autologous bone marrow transplantations: a pilot study. Eur J Haematol 42 (1989) 441-444
10. Meloni G., Vignetti M., Avvisati G., et al. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplant 18 (1996) 693-698
11. Zittoun R., Mandelli F., Willemze R., et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Eng J Med 332 (1995) 217-223
12. Burnett A.K., and McKinnon S. Autologous bone marrow transplantation in first remission AML using nonpurged marrow: update. In: Hagenbeek A., and Lowenberg B. (Eds). Minimal Residual Disease (1986), Martinus Nijhoff, Dordrecht, The Netherlands 211
13. Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339 (1998) 1649-1656
14. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96 (2000) 4075-4083
15. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
16. Fine J.P., and Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999) 496-509
17. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA-identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19 (2005) 2304-2312
18. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 1 (2006) 128-135
19. Stone R., Berg D.T., George S.L., et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Eng J Med 332 (1995) 1671-1677
20. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
21. Alamo J., Shahjahan M., Lazarus H.M., et al. Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplant 36 (2005) 475-479
22. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23 (2005) 1993-2003
23. Molldrem J., Dermime S., Parker K., et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88 (1996) 2450-2457
24. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 188 (2002) 147-154